The recent FDA expansion of Sanofi’s Tzield marks a transformative moment in pediatric endocrinology, moving the needle for early intervention in type 1 diabetes down to children as young as one year old. Ivan Kairatov, a seasoned biopharma expert with a distinguished career in research and
At the very sites where arteries branch and curve, the blood’s mechanical turbulence quietly erodes endothelial defenses while seeding DNA injury that stokes plaque formation yet, paradoxically, also triggers a built-in metabolic countermeasure. New research led by Baylor College of Medicine and
Chloe Botaine sat down with Ivan Kairatov, a Biopharma expert with deep R&D and tech experience, to discuss the European Commission’s approval of a long-acting monoclonal antibody for RSV prevention in newborns and infants. With a single intramuscular dose designed to protect for up to five months,
For patients living with a chronic Achilles rupture that has resisted months of therapy and bracing, every step can feel like a wager against pain, weakness, instability, and the fear that a compromised tendon will fail again during even the simplest tasks. Traditional reconstruction can fix the
A disease that steals movement while leaving thought intact demanded more than incremental symptom care, and that urgency set the stage for a candidate built to confront the fault line where motor neurons first begin to fail. AP-2, now entering first-in-human testing at La Princesa University
Ivan Kairatov brings a biopharma lens to one of the most sensitive decisions in pediatrics: when to give the first hepatitis B vaccine. With a research-and-development background rooted in tech and innovation, he translates probabilistic modeling, clinical epidemiology, and practical workflows into
